Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Parkinson's Disease

  Free Subscription


Articles published in Exp Neurol

Retrieve available abstracts of 34 articles:
HTML format



Single Articles


    August 2022
  1. MEIER JM, Perdikis D, Blickensdorfer A, Stefanovski L, et al
    Virtual deep brain stimulation: Multiscale co-simulation of a spiking basal ganglia model and a whole-brain mean-field model with The Virtual Brain.
    Exp Neurol. 2022;354:114111.
    PubMed     Abstract available


    June 2022
  2. DARCY N, Lofredi R, Al-Fatly B, Neumann WJ, et al
    Spectral and spatial distribution of subthalamic beta peak activity in Parkinson's disease patients.
    Exp Neurol. 2022 Jun 19:114150. doi: 10.1016/j.expneurol.2022.114150.
    PubMed     Abstract available


  3. HUSSEIN A, Tielemans A, Baxter MG, Benson DL, et al
    Cognitive deficits and altered cholinergic innervation in young adult male mice carrying a Parkinson's disease Lrrk2(G2019S) knockin mutation.
    Exp Neurol. 2022 Jun 19:114145. doi: 10.1016/j.expneurol.2022.114145.
    PubMed     Abstract available


  4. RAUSCHENBERGER L, Guttler C, Volkmann J, Kuhn A, et al
    A translational perspective on pathophysiological changes of oscillatory activity in dystonia and parkinsonism.
    Exp Neurol. 2022 Jun 8:114140. doi: 10.1016/j.expneurol.2022.114140.
    PubMed     Abstract available


    May 2022
  5. WIEST C, Torrecillos F, Tinkhauser G, Pogosyan A, et al
    Finely-tuned gamma oscillations: Spectral characteristics and links to dyskinesia.
    Exp Neurol. 2022;351:113999.
    PubMed     Abstract available


    April 2022
  6. PARR-BROWNLIE LC, Itoga CA, Walters JR, Underwood CF, et al
    Oscillatory waveform sharpness asymmetry changes in motor thalamus and motor cortex in a rat model of Parkinson's disease.
    Exp Neurol. 2022 Apr 21:114089. doi: 10.1016/j.expneurol.2022.114089.
    PubMed     Abstract available


    March 2022
  7. PEREIRA MCL, Boese AC, Murad R, Yin J, et al
    Reduced dopaminergic neuron degeneration and global transcriptional changes in Parkinson's disease mouse brains engrafted with human neural stems during the early disease stage.
    Exp Neurol. 2022 Mar 7:114042. doi: 10.1016/j.expneurol.2022.114042.
    PubMed     Abstract available


    February 2022
  8. WENGER N, Vogt A, Skrobot M, Garulli EL, et al
    Rodent models for gait network disorders in Parkinson's disease - a translational perspective.
    Exp Neurol. 2022 Feb 14:114011. doi: 10.1016/j.expneurol.2022.114011.
    PubMed     Abstract available


  9. PENG Y, Schoneberg N, Esposito MS, Geiger JRP, et al
    Current approaches to characterize micro- and macroscale circuit mechanisms of Parkinson's disease in rodent models.
    Exp Neurol. 2022;351:114008.
    PubMed     Abstract available


    January 2022
  10. MIZRAHI-KLIGER AD, Feldmann LK, Kuhn AA, Bergman H, et al
    Etiologies of insomnia in Parkinson's disease - Lessons from human studies and animal models.
    Exp Neurol. 2022;350:113976.
    PubMed     Abstract available


  11. BUSCH JL, Feldmann LK, Kuhn AA, Rosenblum M, et al
    Real-time phase and amplitude estimation of neurophysiological signals exploiting a non-resonant oscillator.
    Exp Neurol. 2022;347:113869.
    PubMed     Abstract available


    November 2021
  12. OH T, Daadi ES, Kim J, Daadi EW, et al
    Dopamine D3 receptor ligand suppresses the expression of levodopa-induced dyskinesia in nonhuman primate model of parkinson's disease.
    Exp Neurol. 2021;347:113920.
    PubMed     Abstract available


    October 2021
  13. MA J, Sun W, Chen S, Wang Z, et al
    The long noncoding RNA GAS5 potentiates neuronal injury in Parkinson's disease by binding to microRNA-150 to regulate Fosl1 expression.
    Exp Neurol. 2021;347:113904.
    PubMed     Abstract available


    September 2021
  14. CHATURVEDI RK, Shukla S, Seth K, Agrawal AK, et al
    Corrigendum to "Zuckerkandl's organ improves long-term survival and function of neural stem cell's derived dopaminergic neurons in parkinsonian rats" [Experimental Neurology Volume 210, Issue 2, April 2008, Pages 608-623].
    Exp Neurol. 2021 Sep 11:113859. doi: 10.1016/j.expneurol.2021.113859.
    PubMed    


  15. YEH TH, Liu HF, Chiu CC, Cheng ML, et al
    PLA2G6 mutations cause motor dysfunction phenotypes of young-onset dystonia-parkinsonism type 14 and can be relieved by DHA treatment in animal models.
    Exp Neurol. 2021 Sep 11:113863. doi: 10.1016/j.expneurol.2021.113863.
    PubMed     Abstract available


    July 2021
  16. LEE JE, Kim HN, Kim DY, Shin YJ, et al
    Memantine exerts neuroprotective effects by modulating alpha-synuclein transmission in a parkinsonian model.
    Exp Neurol. 2021 Jul 13:113810. doi: 10.1016/j.expneurol.2021.113810.
    PubMed     Abstract available


    June 2021
  17. LAPPIN JM, Darke S
    Methamphetamine and heightened risk for early-onset stroke and Parkinson's disease: A review.
    Exp Neurol. 2021 Jun 21:113793. doi: 10.1016/j.expneurol.2021.113793.
    PubMed     Abstract available


    May 2021
  18. BINDA KH, Lillethorup TP, Real CC, Baerentzen SL, et al
    Exercise protects synaptic density in a rat model of Parkinson's disease.
    Exp Neurol. 2021;342:113741.
    PubMed     Abstract available


  19. LIU Z, Yan A, Zhao J, Yang S, et al
    The p75 neurotrophin receptor as a novel intermediate in L-dopa-induced dyskinesia in experimental Parkinson's disease.
    Exp Neurol. 2021;342:113740.
    PubMed     Abstract available


    April 2021
  20. LANGLEY MONICA R, Shivani G, Ay Muhammet PBN, Huajun J, et al
    Characterization of nonmotor behavioral impairments and their neurochemical mechanisms in the MitoPark mouse model of progressive neurodegeneration in Parkinson's disease.
    Exp Neurol. 2021 Apr 8:113716. doi: 10.1016/j.expneurol.2021.113716.
    PubMed     Abstract available


    March 2021
  21. BECKSTEAD MJ, Howell RD
    Progressive parkinsonism due to mitochondrial impairment: Lessons from the MitoPark mouse model.
    Exp Neurol. 2021 Mar 19:113707. doi: 10.1016/j.expneurol.2021.113707.
    PubMed     Abstract available


  22. BERGKVIST L, Johnson ME, Mercado G, Steiner JA, et al
    An extended release GLP-1 analogue increases alpha-synuclein accumulation in a mouse model of prodromal Parkinson's disease.
    Exp Neurol. 2021 Mar 13:113693. doi: 10.1016/j.expneurol.2021.113693.
    PubMed     Abstract available


    January 2021
  23. MCKNIGHT I, Hart C, Park IH, Shim JW, et al
    Genes causing congenital hydrocephalus: Their chromosomal characteristics of telomere proximity and DNA compositions.
    Exp Neurol. 2021;335:113523.
    PubMed     Abstract available


    December 2020
  24. SIMMNACHER K, Krach F, Schneider Y, Alecu JE, et al
    Unique signatures of stress-induced senescent human astrocytes.
    Exp Neurol. 2020;334:113466.
    PubMed     Abstract available


    November 2020
  25. SI XL, Fang YJ, Li LF, Gu LY, et al
    From inflammasome to Parkinson's disease: Does the NLRP3 inflammasome facilitate exosome secretion and exosomal alpha-synuclein transmission in Parkinson's disease?
    Exp Neurol. 2020 Nov 5:113525. doi: 10.1016/j.expneurol.2020.113525.
    PubMed     Abstract available


    October 2020
  26. HAUMESSER JK, Beck MH, Pellegrini F, Kuhn J, et al
    Subthalamic beta oscillations correlate with dopaminergic degeneration in experimental parkinsonism.
    Exp Neurol. 2020;335:113513.
    PubMed     Abstract available


  27. SCHNEIDER JS, Marshall CA, Keibel L, Snyder NW, et al
    A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson's disease.
    Exp Neurol. 2020;335:113514.
    PubMed     Abstract available


    July 2020
  28. WANG Y, Bouabid S, Darvas M, Zhou FM, et al
    The antiparkinson drug ropinirole inhibits movement in a Parkinson's disease mouse model with residual dopamine neurons.
    Exp Neurol. 2020 Jul 28:113427. doi: 10.1016/j.expneurol.2020.113427.
    PubMed     Abstract available


    May 2020
  29. CINAR E, Yalcin-Cakmakli G, Saka E, Ulusoy A, et al
    Modelling cognitive deficits in Parkinson's disease: Is CA2 a gateway for hippocampal synucleinopathy?
    Exp Neurol. 2020 May 10:113357. doi: 10.1016/j.expneurol.2020.113357.
    PubMed     Abstract available


    April 2020
  30. HAQUE A, Samantaray S, Knaryan VH, Capone M, et al
    Calpain mediated expansion of CD4+ cytotoxic T cells in rodent models of Parkinson's disease.
    Exp Neurol. 2020 Apr 14:113315. doi: 10.1016/j.expneurol.2020.113315.
    PubMed     Abstract available


    March 2020
  31. WU G, Lu ZH, Seo JH, Alselehdar SK, et al
    Mice deficient in GM1 manifest both motor and non-motor symptoms of Parkinson's disease; successful treatment with synthetic GM1 ganglioside.
    Exp Neurol. 2020 Mar 9:113284. doi: 10.1016/j.expneurol.2020.113284.
    PubMed     Abstract available


    December 2019
  32. KOUTZOUMIS DN, Vergara M, Pino J, Buddendorff J, et al
    Alterations of the gut microbiota with antibiotics protects dopamine neuron loss and improve motor deficits in a pharmacological rodent model of Parkinson's disease.
    Exp Neurol. 2019;325:113159.
    PubMed     Abstract available


    November 2019
  33. OLIVEIRA LM, Henrique E, Bustelli IB, Netto NFC, et al
    Depletion of hypothalamic hypocretin/orexin neurons correlates with impaired memory in a Parkinson's disease animal model.
    Exp Neurol. 2019;323:113110.
    PubMed     Abstract available


  34. RAUSCHENBERGER L, Knorr S, Al-Zuraiqi Y, Tovote P, et al
    Striatal dopaminergic dysregulation and dystonia-like movements induced by sensorimotor stress in a pharmacological mouse model of rapid-onset dystonia-parkinsonism.
    Exp Neurol. 2019;323:113109.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: